Eli Lilly Acquires CrossBridge Bio for $300 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy LLY?
Source: stocktwits
- Acquisition Details: Eli Lilly announced the acquisition of CrossBridge Bio for $300 million, which includes an upfront payment and a subsequent payment upon achieving specific milestones, aimed at enhancing its oncology drug pipeline.
- New Drug Development: CrossBridge Bio is developing CBB-120, a dual-payload antibody-drug conjugate expected to begin human trials in 2026, designed to improve treatment efficacy for solid tumors.
- Funding Support: Founded in 2023, CrossBridge Bio secured $10 million in seed funding and received a $15 million grant from the Cancer Prevention and Research Institute of Texas in 2025, indicating strong research potential.
- Market Reaction Analysis: Despite a rebound in Eli Lilly's stock following the acquisition announcement, shares have slipped about 13% year-to-date, reflecting cautious market sentiment regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.990
Low
950.00
Averages
1192
High
1500
Current: 903.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
Eli Lilly Reshapes Weight Loss Market with New Launch
- Market Leadership: Eli Lilly's latest launch in the weight loss sector further solidifies its leadership position in this niche, expected to drive revenue growth in light of the escalating global obesity crisis.
- Innovative Drug Launch: The newly approved oral GLP-1 treatment Foundayo, while less effective than Zepbound, is anticipated to attract more cash-paying patients due to its needle-free administration and lower price, potentially achieving sales of $1 billion to $2 billion in the next five years.
- Significant Market Potential: The success of Foundayo is likely to complement Zepbound, with projections suggesting substantial market share growth by 2030, enhancing Eli Lilly's overall performance amid competition from other biotech firms.
- Ongoing Innovation Capability: Eli Lilly's GLP-1 portfolio is regarded as one of its most significant breakthroughs in history, with plans to introduce the triple agonist retatrutide targeting other weight loss niches, showcasing the company's strong potential for innovation and market expansion.
See More
Eli Lilly's Innovation Drives Long-Term Growth
- Market Opportunity: Eli Lilly's new drug Foundayo is projected to generate sales of $1 billion to $2 billion in its first year, and while it may not be as effective as Zepbound, its lower cost as an oral GLP-1 option could attract more patients, driving growth in the weight-loss market.
- Product Innovation: The launch of Foundayo not only provides a needle-free treatment option for cash-paying patients but also reduces storage requirements, thereby improving adherence among patients who are apprehensive about injections, further solidifying Eli Lilly's leadership in the weight-loss medication space.
- Long-Term Strategy: Eli Lilly's ongoing innovation in the GLP-1 sector, particularly the complementarity with Zepbound, suggests significant sales growth potential in the coming years, with projections indicating that tirzepatide could reach the highest sales peak in pharmaceutical history by 2030.
- Financial Performance: Eli Lilly has experienced rapid revenue and earnings growth in recent years, outpacing its peers, and its dividends have increased by 239% over the past decade, highlighting its attractiveness and stability as a long-term investment.
See More
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
Eli Lilly Reshapes Weight Loss Market with New Launch
- Market Leadership: Eli Lilly's latest launch in the weight loss sector further solidifies its leadership position in this niche, expected to drive revenue growth in light of the escalating global obesity crisis.
- Innovative Drug Launch: The newly approved oral GLP-1 treatment Foundayo, while less effective than Zepbound, is anticipated to attract more cash-paying patients due to its needle-free administration and lower price, potentially achieving sales of $1 billion to $2 billion in the next five years.
- Significant Market Potential: The success of Foundayo is likely to complement Zepbound, with projections suggesting substantial market share growth by 2030, enhancing Eli Lilly's overall performance amid competition from other biotech firms.
- Ongoing Innovation Capability: Eli Lilly's GLP-1 portfolio is regarded as one of its most significant breakthroughs in history, with plans to introduce the triple agonist retatrutide targeting other weight loss niches, showcasing the company's strong potential for innovation and market expansion.
See More
Eli Lilly's Innovation Drives Long-Term Growth
- Market Opportunity: Eli Lilly's new drug Foundayo is projected to generate sales of $1 billion to $2 billion in its first year, and while it may not be as effective as Zepbound, its lower cost as an oral GLP-1 option could attract more patients, driving growth in the weight-loss market.
- Product Innovation: The launch of Foundayo not only provides a needle-free treatment option for cash-paying patients but also reduces storage requirements, thereby improving adherence among patients who are apprehensive about injections, further solidifying Eli Lilly's leadership in the weight-loss medication space.
- Long-Term Strategy: Eli Lilly's ongoing innovation in the GLP-1 sector, particularly the complementarity with Zepbound, suggests significant sales growth potential in the coming years, with projections indicating that tirzepatide could reach the highest sales peak in pharmaceutical history by 2030.
- Financial Performance: Eli Lilly has experienced rapid revenue and earnings growth in recent years, outpacing its peers, and its dividends have increased by 239% over the past decade, highlighting its attractiveness and stability as a long-term investment.
See More
